Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NYSE:ZYME) – Equities researchers at Lifesci Capital issued their Q1 2025 earnings estimates for Zymeworks in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will post earnings per share of ($0.50) for the quarter. Lifesci Capital has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Lifesci Capital also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.36) EPS, Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.81) EPS and FY2026 earnings at ($1.77) EPS.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target on the stock in a report on Monday, December 16th. HC Wainwright lifted their price target on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, March 10th. Wells Fargo & Company lifted their price target on shares of Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Finally, Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zymeworks has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Trading Down 2.4 %

NYSE ZYME opened at $12.25 on Thursday. The firm’s fifty day simple moving average is $13.92 and its two-hundred day simple moving average is $13.64. Zymeworks has a 12-month low of $7.97 and a 12-month high of $17.70. The firm has a market capitalization of $852.32 million, a P/E ratio of -8.17 and a beta of 1.13.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Polar Asset Management Partners Inc. acquired a new position in shares of Zymeworks in the fourth quarter worth about $527,000. Voloridge Investment Management LLC acquired a new position in shares of Zymeworks in the fourth quarter worth about $640,000. Point72 Asset Management L.P. raised its position in shares of Zymeworks by 565.8% in the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock worth $4,833,000 after acquiring an additional 280,544 shares during the period. Nuveen Asset Management LLC raised its position in shares of Zymeworks by 0.4% in the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after acquiring an additional 886 shares during the period. Finally, Deutsche Bank AG raised its position in shares of Zymeworks by 1.2% in the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock worth $22,645,000 after acquiring an additional 17,849 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity at Zymeworks

In related news, insider Paul Andrew Moore sold 21,200 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the completion of the transaction, the insider now directly owns 14,741 shares in the company, valued at $219,935.72. The trade was a 58.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ecor1 Capital, Llc bought 468,356 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $12.48 per share, with a total value of $5,845,082.88. Following the completion of the transaction, the director now directly owns 16,802,141 shares of the company’s stock, valued at $209,690,719.68. This trade represents a 2.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,392,585 shares of company stock worth $17,914,519 and sold 89,601 shares worth $1,336,847. 1.92% of the stock is currently owned by insiders.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.